Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt

Breast Neoplasm: early-phase trial registry

9 of 27 indexed Breast Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #598 of 28,707 conditions by registered trial count.

27 US clinical trials · 9 currently recruiting · #598 of 28,707 conditions by registered trial count

Breast Neoplasm: 27 US clinical trials tracked, 9 recruiting.

Breast Neoplasm is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 3 of these trials.

Enrollment posture brief

Registry condition breast-neoplasm

OPEN 9 | RECR 33% | LATE 2 | EARLY 13 | RANK #598 | SPON 3

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Alopecia Areata55.6%Acute Ischemic Stroke44.4%Breast Neoplasm (this)33%Adenocarcinoma25.9%Acne22.2%
Open-enrollment share among volume-matched conditions near Breast Neoplasm

Breast Neoplasm lists 9 open slots (33% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Breast Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Neoplasm is recruiting below its size-band peers.

    9 of 27 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Breast Neoplasm trials is spread across many organizations.

    Mayo Clinic accounts for 3 of 27 trials (11.1%). 19 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Neoplasm enrolment sits around 107 participants.

    Median target enrolment is 107 among the 27 trials that report a genuine target (sentinel values excluded). 13 of those (48.1%) plan for fewer than 100 participants.

  4. Breast Neoplasm research is mostly interventional.

    23 interventional and 4 observational studies make up this index (85.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 26Phase 32

Open and recent trials

27 total, page 1 of 1

RECRUITING 550 participants

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring

Mayo Clinic

NCT04799535

RECRUITING Phase 3 404 participants

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

BriaCell Therapeutics Corporation

NCT06072612

RECRUITING Phase 2 185 participants

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Baylor Breast Care Center

NCT05020860

RECRUITING NA 150 participants

Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction

University of Alabama at Birmingham

NCT06294574

RECRUITING Phase 2 132 participants

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Proton Collaborative Group

NCT01766297

RECRUITING NA 120 participants

Cryoablation vs Lumpectomy in T1 Breast Cancers

Washington University School of Medicine

NCT05505643

RECRUITING NA 70 participants

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

Mayo Clinic

NCT06058650

RECRUITING Phase 1 48 participants

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

MBQ Pharma

NCT06075810

RECRUITING 30 participants

Surviving Daily Life

Thomas Jefferson University

NCT07054723

ACTIVE NOT RECRUITING Phase 3 368 participants

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Eli Lilly and Company

NCT05169567

ACTIVE NOT RECRUITING Phase 2 220 participants

Proton Radiation for Stage II/III Breast Cancer

Proton Collaborative Group

NCT01758445

ACTIVE NOT RECRUITING NA 130 participants

Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer

M.D. Anderson Cancer Center

NCT03141437

ACTIVE NOT RECRUITING Phase 1 48 participants

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Carisma Therapeutics

NCT04660929

ACTIVE NOT RECRUITING 36 participants

A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

Mayo Clinic

NCT05889988

ACTIVE NOT RECRUITING Phase 1 30 participants

[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer

University of Pennsylvania

NCT02284919

ACTIVE NOT RECRUITING Phase 1 20 participants

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

University of Pennsylvania

NCT02608216

COMPLETED NA 600 participants

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

Wake Forest University Health Sciences

NCT03935282

COMPLETED NA 300 participants

Study of Web-based Decision Aids for Increasing Breast Cancer Chemoprevention in the Primary Care Setting

Columbia University

NCT03069742

COMPLETED Phase 2 267 participants

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Novartis Pharmaceuticals

NCT00107016

COMPLETED NA 140 participants

Post-treatment Care of Breast Cancer Survivors

Columbia University

NCT00821288

COMPLETED Phase 1 107 participants

Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer

National Cancer Institute (NCI)

NCT00001507

COMPLETED Phase 2 75 participants

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

University of Alabama at Birmingham

NCT00530868

COMPLETED Phase 2 65 participants

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Bayer

NCT00313248

COMPLETED Phase 1 51 participants

Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy

National Cancer Institute (NCI)

NCT00001440

COMPLETED 50 participants

Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

NCT00001496

COMPLETED NA 20 participants

Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups

Mary Radomski

NCT04767464

COMPLETED Phase 1 16 participants

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Takeda

NCT00034281

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 6
Phase 3 2

Named interventions

Most-linked intervention names on Breast Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Proton Radiotherapy Radiation
2 trials
Compass Course Other
1 trials
Sagopilone (ZK 219477) Drug
1 trials
TAK-165 Drug
1 trials
AH-HA Tool in the EPIC EHR Other
1 trials
Facing Forward Behavioral
1 trials
Survivorship Intervention Behavioral
1 trials
RAD001, Letrozole 2.5mg Drug
1 trials

US sites by state

Facility locations filed on Breast Neoplasm trials. A trial with sites in several states counts in each.

California 8 trials
Pennsylvania 7 trials
Maryland 6 trials
Texas 5 trials
New York 5 trials
Minnesota 5 trials
Illinois 5 trials
Arizona 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Breast Neoplasm page

27 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 9 Breast Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Mayo Clinic sponsors the most Breast Neoplasm trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Neoplasm condition card totals 27 registered trials; most-linked intervention Proton Radiotherapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.